MYL9

Across TCGA pan-cancer cohorts, MYL9 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MYL9’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MYL9 RNA is repressed in tumor relative to normal tissue. In most cancer types MYL9 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

BLCA, LUAD, and KICH are the cancer types where MYL9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYL9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−5.785	<.001	11	view →
LUAD	Female	All	−1.755	<.001	9	view →
KICH	Female	All	−2.945	<.001	8	view →
LUSC	Male	III,IV	−2.809	<.001	8	view →
COAD	Male	All	−2.405	<.001	8	view →
BRCA	All	II,III,IV	−1.597	<.001	8	view →
STAD	Female	All	−3.615	<.001	7	view →
UCEC	All	III,IV	−4.373	<.001	6	view →
READ	All	All	−3.333	.002	4	view →
CHOL	All	All	+2.517	<.001	3	view →
HNSC	All	III,IV	+1.000	.012	3	view →
LIHC	All	All	+0.645	.009	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MYL9–BLCA

Open the BLCA breakdown →